Abstract:Background PD-1/PD-L1 blockade is responsible for the majority of the success of cancer immunotherapy. 1 However, only 14% of patients eligible to receive checkpoint blockade achieve objected clinical responses. 2 3 The reason for the failure of PD-L1 blockade may be attributed to the recently appreciated widespread expression of PD-L2 across human cancers and its immunosuppresive stromal cells. 4 PD-L2 expression was shown to be as or more predictive of response to PD-1 blockade than PD-L14. PD-L2 traditionally was dismissed as functionally redundant to PD-L1 varying only in pattern of expression. We hypothesize that PD-L2 engages PD-1 to generate a distinct inhibitory signal from that of PD-L1, and antibody mediated blockade and depletion of PD-L2+ cells may promote anti-tumor immunity that is superior to PD-L1 blockade alone. Methods Cell based bioluminescent assay demonstrated the nature of regulation mediated by human PD-L2 through the PD-1 co-receptor. RNA-sequencing identified key differences in the signaling pathways generated in Jurkat T cells by PD-1 binding to PD-L1 or PD-L2. Multidimensional flow cytometry determined the differential effects of PD-L1 and PD-L2 on human T cell proliferation and effector function. Western blot elucidated the temporal kinetics of inhibition mediated by PD-L1 and PD-L2. Survival studies in murine syngeneic lymphoma model evaluated the efficacy of antibody mediated blockade and depletion of PD-L2+ cells. Results We validated that human PD-L2, unlike murine PD-L2, generates a purely co-inhibitory signal in human T cells, albeit with a reduced inhibitory potential relative to PD-L1. We discovered significant differences in downstream T cell signaling pathways generated by PD-L1 versus PD-L2 through PD-1 engagement. Human PD-L1 and PD-L2 differentially modulated T cell effector function and proliferation with PD-L2 preferentially arresting T cells in S-phase of cell cycle. PD-L1 and PD-L2 also differed in the temporal kinetics of dephosphorylation of the membrane proximal proteins in the TCR-CD3 signaling complex. We observed that combination blockade of PD-L1 and PD-L2 improves on blockade of PD-L1 alone resulting in increased production of IL-2 and IFNγ in primary human mixed lymphocyte reactions. Our data in a syngeneic murine model of EL4 showed that effector-function capable PD-L2 blocking antibodies are therapeutically superior to PD-L1 or PD-L2 blockade alone. Conclusions We are the first to report on T cell immunoregulatory functions of PD-L2 which are distinct from those of PD-L1, and demonstrate that the more tumor-selective expression pattern of PD-L2 relative to PD-L1 provides a therapeutic advantage to effector-function capable PD-L2 antibodies. Acknowledgements AS was supported by the CPRIT Research Training Grant(RP170067) References Ribas A, Wolchok JD (2018). Cancer immunotherapy using checkpoint blockade. Science 359 :1350–1355. Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D (2018). Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362 . Haslam A, Prasad V (2019). Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2 :e192535. Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, Handa M, Tomassini JE, McClanahan T (2017). PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 23 :3158–3167.

Cross-reactivity of Anti-Programmed Death Ligand 2 Polyclonal Antibody in Mouse Tissues

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

Preparation and characterization of a novel monoclonal antibody against human PD-1

Preparation and Characterization of a Novel Monoclonal Antibody Against Human PD-L2 (B7-DC)

Programmed Death 1 Ligand (Pd-L) 1 And Pd-L2 Limit Autoimmune Kidney Disease: Distinct Roles

Preparation and application of anti-human PD-L1 monoclonal antibodies

[Preparation of Two Mouse Anti-Human PD-1 Monoclonal Antibodies and Identification of Their Biological Characteristics].

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies

Overexpression of Programmed Death Ligand 1 in Dendritic Cells Inhibits Allogeneic Lymphocyte Activation in Mice

Human and mouse PD-L1: similar molecular structure, but different druggability profiles

Expressions of PD-L2 in Mouse Myeloid Dendritic Cells and Its Role in Activation of T Lymphocytes

[Preparation and identification of human soluble sPD-L1 and its antibodies]

Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies

Abstract 3393: Using Protein Microarray Technology to Screen Anti-Pd-1 Monoclonal Antibodies for Specificity and Applications in Anatomic Pathology

Using Protein Microarray Technology To Screen Anti-Pd-1 Monoclonal Antibodies For Specificity And Applications In Anatomic Pathology

233 Human PD-L2 triggers a unique T cell inhibitory program through PD-1 engagement distinct from that of PD-L1

Identification of Programmed Cell Death 1 and Its Ligand in the Testicular Tissue of Mice

Differential Involvement of Programmed Cell Death Ligands in Skin Immune Responses

PD-L1-deficient Mice Show That PD-L1 on T Cells, Antigen-Presenting Cells, and Host Tissues Negatively Regulates T Cells

Screening and characterization of aptamers for recombinant human programmed death-1 and recombinant extracellular domain of human programmed death ligand-1